Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1454 - 70-gene signature, an encouraging prognostic tool to guide adjuvant therapy in Early Breast Cancer. (87P)


18 Nov 2017


Poster lunch


Translational Research;  Breast Cancer


Alberto Cunquero Tomas


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


A. Cunquero Tomas1, C. Avila Andrade2, A.B. Fernandez Diaz2, M. Meri Abad2, I. Shaheen3, L. Condori Farfan2, A. Rodriguez Huaman2, V. Sforza1, F.D.A. Aparisi Aparisi1, M.J. Safont Aguilera2, A. Blasco Cordellat2, M. Gil Raga1, C. Caballero Diaz1, A. Berrocal2, M.C. Godes Sanz de Bremond1, A. Pérez4, V. Iranzo Gonzalez-Cruz2, C. Camps Herrero2

Author affiliations

  • 1 Medical Oncology, Consorcio Hospital General Universitario Valencia, 46014 - Valencia/ES
  • 2 Medical Oncology, General University Hospital of Valencia, 46014 - VALENCIA/ES
  • 3 Medical Oncology, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 4 Pathology, Consorcio Hospital General Universitario Valencia, 46014 - Valencia/ES


Abstract 1454


Prognosis of early breast cancer (EBC) after surgery seems to be tied to both clinical and molecular features. Based on this, the addition of adjuvant chemotherapy (ACT) in ER+ HER2-, moderately differentiated, low ER expression or moderate tumor burden EBC is made, assuming a predictive role of these features in ACT benefit. There are patients who, based on these data, could abstain ACT without an increase in the risk of early relapse or decrease in survival. It is in these patients that molecular platforms, either 70-gene (Mammaprint®) or 21-gene (OncotypeDx®) signatures, combined with clinical features, would help decision making, sparing toxicities to these patients.


We analyzed 89 of 850 first visits (2014/17) with ER+ HER2- EBC,


Mean 57 year-old patients at diagnosis, 60% postmenopausal. 53% Luminal B, all Luminal type by Blueprint®. 79% T1 and 16% N1mic. Bad prognosis encouraging ACT in 57% and 33% of patients based on clinical and statistical characteristics, respectively. 36% ACT indication on molecular basis, 25% of reduction of ACT indication. In subgroup analysis, 55% of high-risk patients according to clinical criteria were low-risk Mammaprint, with 33% who went from low to high risk of relapse. This implies a 20% decrease in chemotherapy treatments. In addition, 2 or more clinical risk factors may predict a high-risk result in the 70-gene signature assay, with likeliness of poor prognosis and ACT potential benefit. With a median follow-up of 15 months, no relapses have been noticed.


Prognosis based on clinically significant reduction of the indication of ACT (around 25%) without affecting the rate of relapse has been noticed, with data suggesting prediction of gene-signature assay results according to the number of clinical risk factor present. A longer follow-up time and a larger number of patients are needed to confirm these results.

Clinical trial identification

Legal entity responsible for the study

Consorcio Hospital General Universitario Valencia




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.